Robert Bujak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robert Bujak has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Władysław Sinkiewicz
II Katedra Kardiologii, Uniwersytet Mikołaja Kopernika w Toruniu, Collegium Medicum, Bydgoszcz
10 shared publications - Jan Błażejewski
2nd Chair of Cardiology, L. Rydygier Medical College in Bydgoszcz, Nicolaus Copernicus University in Torun, Dr. J. Biziel University Hospital no. 2 in Bydgoszcz, Poland, Ujejskiego 75, 85-168 Bydgoszcz, Poland
8 shared publications - Danuta Karasek
II Clinic of Cardiology, Nicolaus Copernicus University in Toruń, L. Rydygier Collegium Medicum in Bydgoszcz, University Hospital No 2 in Bydgoszcz, Poland
6 shared publications Joanna Banach
4 shared publications- Wojciech Balak
2nd Department of Cardiology,Ludwik Rydygier CollegiumMedicumin Bydgoszcz,Nicolaus CopernicusUniversityin Toruń, Jan BizielUniversityHospitalNo. 2 in Bydgoszcz, Bydgoszcz, Poland
4 shared publications - Jacek Kubica
Collegium Medicum, Nicolaus Copernicus University, 85-094 Bydgoszcz, Poland
3 shared publications
Latest Publications
- 21 November 2020
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 190 (3) , 981-986
Resveratrol and cardiovascular system—the unfulfilled hopes
Introduction Resveratrol is a natural polyphenolic compound with a stilbene structure endowed with multiple health-promoting effects. Among phenolic compounds, resveratrol is assigned a leading role in the health-promoting effects of red wine. Methods The aim of the study was to assess the effect of resveratrol on the cardiovascular system in the experimental and clinical studies conducted so far. Moreover, the paper discusses the results of the most recent meta-analyses assessing resveratrol’s therapeutic effect on the cardiovascular system in humans. Results In animal and preclinical studies, resveratrol has demonstrated a wide physiological and biochemical spectrum of activity, including antioxidant, anti-inflammatory, antiplatelet, and anticoagulant activities, which translated into its health-promoting effects on the cardiovascular system. The performed meta-analyses allow to confirm such an impact, however, after the assessment with the use of the SYRCLE’s tool, these studies are burdened with a high risk of bias, and the results are not clearly presented. Conclusion Despite numerous articles and clinical studies, the convincing beneficial mechanisms of resveratrol as well as its health-promoting effects in cardiovascular diseases have not been clearly confirmed in humans. Therefore, there is a need for further clinical studies, especially randomized, double-blind, placebo-controlled trials to objectively confirm the possible health-promoting effects of this substance and to determine both the efficacy and safety, and possible therapeutic potential.
- 21 November 2020
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 190 (3) , 981-986
Resveratrol and cardiovascular system—the unfulfilled hopes
Introduction Resveratrol is a natural polyphenolic compound with a stilbene structure endowed with multiple health-promoting effects. Among phenolic compounds, resveratrol is assigned a leading role in the health-promoting effects of red wine. Methods The aim of the study was to assess the effect of resveratrol on the cardiovascular system in the experimental and clinical studies conducted so far. Moreover, the paper discusses the results of the most recent meta-analyses assessing resveratrol’s therapeutic effect on the cardiovascular system in humans. Results In animal and preclinical studies, resveratrol has demonstrated a wide physiological and biochemical spectrum of activity, including antioxidant, anti-inflammatory, antiplatelet, and anticoagulant activities, which translated into its health-promoting effects on the cardiovascular system. The performed meta-analyses allow to confirm such an impact, however, after the assessment with the use of the SYRCLE’s tool, these studies are burdened with a high risk of bias, and the results are not clearly presented. Conclusion Despite numerous articles and clinical studies, the convincing beneficial mechanisms of resveratrol as well as its health-promoting effects in cardiovascular diseases have not been clearly confirmed in humans. Therefore, there is a need for further clinical studies, especially randomized, double-blind, placebo-controlled trials to objectively confirm the possible health-promoting effects of this substance and to determine both the efficacy and safety, and possible therapeutic potential.
- 23 November 2016
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 74 (11) , 1356
Churg-Strauss syndrome with endocardial injury, clot formation in heart’s chambers, and neurological complications
- 23 November 2016
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 74 (11) , 1356
Churg-Strauss syndrome with endocardial injury, clot formation in heart’s chambers, and neurological complications
- 1 January 2012
- Vol. 70 (1) , 85-7
Giant post-infarction pseudoaneurysm of the left ventricle manifesting as severe heart failure.
A 57 year-old female was admitted for chronic heart failure (HF) with NYHA class IV symptoms. Transthoracic echocardiography revealed ruptured left ventricular (LV) lateral and posterior wall between their basal and middle segments resulting in giant, round pseudoaneurysm formation with a diameter of 12 cm. Bidirectional flow through a 2.9 cm orifice between the LV and the pseudoaneurysm cavity was shown. A 12-cm diameter pseudoaneurysm was resected and the orifice was closed with a Dacron patch. Twelve months after the diagnosis, the patient is in a stable condition with NYHA class II HF symptoms.
- 1 January 2012
- Vol. 70 (1) , 85-7
Giant post-infarction pseudoaneurysm of the left ventricle manifesting as severe heart failure.
A 57 year-old female was admitted for chronic heart failure (HF) with NYHA class IV symptoms. Transthoracic echocardiography revealed ruptured left ventricular (LV) lateral and posterior wall between their basal and middle segments resulting in giant, round pseudoaneurysm formation with a diameter of 12 cm. Bidirectional flow through a 2.9 cm orifice between the LV and the pseudoaneurysm cavity was shown. A 12-cm diameter pseudoaneurysm was resected and the orifice was closed with a Dacron patch. Twelve months after the diagnosis, the patient is in a stable condition with NYHA class II HF symptoms.
- 1 January 2011
- Vol. 69 (1) , 61
[Severe, thromboembolic pulmonary hypertension with recurrent pulmonary embolism and right heart thrombi in a patient with past myocardial infarction, cerebral ischaemic stroke and small intestine necrosis].
Chronic thromboembolic pulmonary hypertension (CTEPH) is a chronic progressive disease of pulmonary circulation characterised by indistinct ethiopathogenesis. We present a case of a 50 year-old male with thrombophilia of unknown origin leading to the formation of multiple thrombi within venous circulation followed by episodes of acute pulmonary embolism resulting ultimately in acute heart failure in the course of developing CTEPH. Unfortunately, despite the wide range of haemostasis laboratory tests we were not able to define the type of coagulation abnormality. Owing to the efficient cooperation between cardiologists and cardiosurgeons it was possible to save patient's life.
- 1 January 2011
- Vol. 69 (1) , 61
[Severe, thromboembolic pulmonary hypertension with recurrent pulmonary embolism and right heart thrombi in a patient with past myocardial infarction, cerebral ischaemic stroke and small intestine necrosis].
Chronic thromboembolic pulmonary hypertension (CTEPH) is a chronic progressive disease of pulmonary circulation characterised by indistinct ethiopathogenesis. We present a case of a 50 year-old male with thrombophilia of unknown origin leading to the formation of multiple thrombi within venous circulation followed by episodes of acute pulmonary embolism resulting ultimately in acute heart failure in the course of developing CTEPH. Unfortunately, despite the wide range of haemostasis laboratory tests we were not able to define the type of coagulation abnormality. Owing to the efficient cooperation between cardiologists and cardiosurgeons it was possible to save patient's life.
- 1 January 2011
- Vol. 69 (3) , 294-7
[Severe tachycardiomyopathy and thrombus in the left atrial appendage--a case report].
We describe a case of severe left ventricular (LV) heart failure caused by tachycardiomyopathy with concomitant presence of unsolved thrombus in left atrial appendage despite effective oral anticoagulant treatment. Successful ablation of atrial flutter and atrioventricular nodal reentry tachycardia entailed resolution of heart failure symptoms and normalisation of LV function.
- 1 January 2011
- Vol. 69 (3) , 294-7
[Severe tachycardiomyopathy and thrombus in the left atrial appendage--a case report].
We describe a case of severe left ventricular (LV) heart failure caused by tachycardiomyopathy with concomitant presence of unsolved thrombus in left atrial appendage despite effective oral anticoagulant treatment. Successful ablation of atrial flutter and atrioventricular nodal reentry tachycardia entailed resolution of heart failure symptoms and normalisation of LV function.
- 1 January 2011
- Vol. 69 (6) , 593
[Successful therapy and rehabilitation following stroke in a pregnant woman with prosthetic aortic valve].
This report describes a case of a 40 year-old woman with implanted aortic prosthetic valve, who experienced thrombo-embolic complication in a form of ischaemic stroke in 15 week of pregnancy. At the beginning of the event, the patient suffered from mixed aphasia, right-side paresis and depressive syndrome. Thanks to cooperation of many specialists, especially rehabilitation team, she restored overall physical efficiency, speaking ability, delivered a healthy child, and returned to normal family and social activity. Problems of anti-thrombotic therapy during pregnancy in patients with prosthetic valves are discussed.
- 1 January 2011
- Vol. 69 (6) , 593
[Successful therapy and rehabilitation following stroke in a pregnant woman with prosthetic aortic valve].
This report describes a case of a 40 year-old woman with implanted aortic prosthetic valve, who experienced thrombo-embolic complication in a form of ischaemic stroke in 15 week of pregnancy. At the beginning of the event, the patient suffered from mixed aphasia, right-side paresis and depressive syndrome. Thanks to cooperation of many specialists, especially rehabilitation team, she restored overall physical efficiency, speaking ability, delivered a healthy child, and returned to normal family and social activity. Problems of anti-thrombotic therapy during pregnancy in patients with prosthetic valves are discussed.
- 1 January 2011
- Vol. 69 (9) , 948
[Recurrent cardiac tamponade and sepsis in a patient with rheumatoid arthritis].
Exudative pericarditis is found in 30-50% of the patients with rheumatoid arthritis (RA), particularly in later stages of the disease. Most cases present with no or few symptoms. We report a case of a 68 year-old male with a history of mild RA who developed exudative pericarditis leading to recurrent cardiac tamponade requiring repeated pericardiocenteses. Treatment with glucocorticosteroids, methotrexate and colchicine proved ineffective in preventing the recurrences. Immunosuppression contributed to the development of sepsis caused by Enterobacter cloacae and resulting in the patient's death.
- 1 January 2011
- Vol. 69 (9) , 948
[Recurrent cardiac tamponade and sepsis in a patient with rheumatoid arthritis].
Exudative pericarditis is found in 30-50% of the patients with rheumatoid arthritis (RA), particularly in later stages of the disease. Most cases present with no or few symptoms. We report a case of a 68 year-old male with a history of mild RA who developed exudative pericarditis leading to recurrent cardiac tamponade requiring repeated pericardiocenteses. Treatment with glucocorticosteroids, methotrexate and colchicine proved ineffective in preventing the recurrences. Immunosuppression contributed to the development of sepsis caused by Enterobacter cloacae and resulting in the patient's death.
- 1 January 2010
- Vol. 68 (1) , 80
[The case of surgically treated severe thromboemboic pulmonary hypertension developing in the course of recurrent pulmonary embolism].
A case of a patient with surgically treated progressive thromboembolic pulmonary hypertension in the course of recurrent pulmonary embolism resulting from deep vein thrombosis is presented. Acute embolic episode seems to have crucial role as an initiating factor triggering the cascade of unfavorable changes in pulmonary vasculature. The paper stresses the role of systematic clinical and echocardiographic control of patients after pulmonary embolism in order to diagnose developing complications as soon as possible. It would allow to introduce efficient treatment and improve prognosis.
- 1 January 2010
- Vol. 68 (1) , 80
[The case of surgically treated severe thromboemboic pulmonary hypertension developing in the course of recurrent pulmonary embolism].
A case of a patient with surgically treated progressive thromboembolic pulmonary hypertension in the course of recurrent pulmonary embolism resulting from deep vein thrombosis is presented. Acute embolic episode seems to have crucial role as an initiating factor triggering the cascade of unfavorable changes in pulmonary vasculature. The paper stresses the role of systematic clinical and echocardiographic control of patients after pulmonary embolism in order to diagnose developing complications as soon as possible. It would allow to introduce efficient treatment and improve prognosis.
- 1 January 2008
- Vol. 15 (1) , 63-70
The reliability of noninvasive cardiac output measurement using the inert gas rebreathing method in patients with advanced heart failure.
Impaired cardiac output (CO) is a key element of heart failure (HF). So far, there has been no simple, reliable, inexpensive and non-invasive CO measurement method feasible for clinical practice. Not a single diagnostic test has been elaborated to diagnose and monitor HF. The aim of the study was the evaluation of the reliability of a new, non-invasive CO measurement device utilizing an inert gas rebreathing technique and an infrared photoacoustic gas analyzer, in comparison with standard invasive methods. In 21 patients with advanced HF (NYHA classes III and IV) undergoing cardiac catheterization as a routine hemodynamic evaluation before heart transplantation, CO measurements with the tested non-invasive method were carried out during invasive examination. CO measured by the inert gas rebreathing technique (CO(RB)), according to the statistical Bland-Altman method, was, on average, 0.1 L/min higher than that determined by thermodilution (CO(TD)) and 0.006 L/min higher than the CO determined by the Fick formula (CO(Fick)). This magnitude of difference equals 2.8% of CO(TD) and 0.15% of CO(Fick) values. The limits of agreement between CO(RB) and CO(TD) were +/- 1.4 L/min, and between CO(RB) and CO(Fick) +/- 1.3 L/min. In the subgroup with atrial fibrillation, the mean difference between tested and reference methods (0.3 +/- 1.0 L/min for both CO(TD) and CO(Fick)) was higher than in the sinus rhythm subgroup (0.06 +/- 1.5 L/min for CO(TD) and 0.08 +/- 1.5 for CO(Fick)). CO measurement with the inert gas rebreathing method utilizing an infrared photoacoustic gas analyzer seems reliable enough to be employed in clinical practice. Being non-invasive, it may well be used for repeated determinations in patients with HF.
- 1 January 2008
- Vol. 15 (1) , 63-70
The reliability of noninvasive cardiac output measurement using the inert gas rebreathing method in patients with advanced heart failure.
Impaired cardiac output (CO) is a key element of heart failure (HF). So far, there has been no simple, reliable, inexpensive and non-invasive CO measurement method feasible for clinical practice. Not a single diagnostic test has been elaborated to diagnose and monitor HF. The aim of the study was the evaluation of the reliability of a new, non-invasive CO measurement device utilizing an inert gas rebreathing technique and an infrared photoacoustic gas analyzer, in comparison with standard invasive methods. In 21 patients with advanced HF (NYHA classes III and IV) undergoing cardiac catheterization as a routine hemodynamic evaluation before heart transplantation, CO measurements with the tested non-invasive method were carried out during invasive examination. CO measured by the inert gas rebreathing technique (CO(RB)), according to the statistical Bland-Altman method, was, on average, 0.1 L/min higher than that determined by thermodilution (CO(TD)) and 0.006 L/min higher than the CO determined by the Fick formula (CO(Fick)). This magnitude of difference equals 2.8% of CO(TD) and 0.15% of CO(Fick) values. The limits of agreement between CO(RB) and CO(TD) were +/- 1.4 L/min, and between CO(RB) and CO(Fick) +/- 1.3 L/min. In the subgroup with atrial fibrillation, the mean difference between tested and reference methods (0.3 +/- 1.0 L/min for both CO(TD) and CO(Fick)) was higher than in the sinus rhythm subgroup (0.06 +/- 1.5 L/min for CO(TD) and 0.08 +/- 1.5 for CO(Fick)). CO measurement with the inert gas rebreathing method utilizing an infrared photoacoustic gas analyzer seems reliable enough to be employed in clinical practice. Being non-invasive, it may well be used for repeated determinations in patients with HF.
- 1 January 2008
- Vol. 15 (2) , 122-8
Immunoglobulin E in patients with ischemic heart disease.
In recent years, increased serum immunoglobulin E (IgE) concentration in patients with cardiovascular diseases has been generating more and more interest. It is as yet unknown, however, if the increased IgE level is a marker of future coronary incidents and whether it may be regarded as an ischemic heart disease risk factor, or if it is indicative of the participation of antibodies in an inflammatory reaction to tissue damage. The aim of the study was to evaluate what significant changes in the total IgE concentration occur in patients with different forms of ischemic heart disease (IHD) and whether the concentration differs in comparison to healthy people. Additionally, we evaluated the dynamics of serum IgE concentration in patients with acute myocardial infarction. The study included 195 patients: 80 acute myocardial infarction (AMI) patients, 58 patients with troponin-negative acute coronary syndrome (ACS) and 57 patients with stable angina pectoris, with negative personal and family history of allergy. The control group consisted of 39 healthy, age-matched individuals. Serum IgE concentration measurements were carried out with an Uni-cap Total IgE kit, using the FEIA technique. In patients suffering from any form of ischemic heart disease, significantly increased concentrations of serum immunoglobulin E were found, as compared to the control group of healthy individuals. Changes of IgE serum concentration on the 1(st) day, 7(th) day, 14(th) day and 40(th) day after AMI did not reveal any significant differences. Males with AMI turned out to have significantly higher immunoglobulin concentrations than females. The observed higher serum IgE concentration in patients with IHD may serve as evidence contribution to atherogenesis and myocardial ischemia.
- 1 January 2008
- Vol. 15 (2) , 122-8
Immunoglobulin E in patients with ischemic heart disease.
In recent years, increased serum immunoglobulin E (IgE) concentration in patients with cardiovascular diseases has been generating more and more interest. It is as yet unknown, however, if the increased IgE level is a marker of future coronary incidents and whether it may be regarded as an ischemic heart disease risk factor, or if it is indicative of the participation of antibodies in an inflammatory reaction to tissue damage. The aim of the study was to evaluate what significant changes in the total IgE concentration occur in patients with different forms of ischemic heart disease (IHD) and whether the concentration differs in comparison to healthy people. Additionally, we evaluated the dynamics of serum IgE concentration in patients with acute myocardial infarction. The study included 195 patients: 80 acute myocardial infarction (AMI) patients, 58 patients with troponin-negative acute coronary syndrome (ACS) and 57 patients with stable angina pectoris, with negative personal and family history of allergy. The control group consisted of 39 healthy, age-matched individuals. Serum IgE concentration measurements were carried out with an Uni-cap Total IgE kit, using the FEIA technique. In patients suffering from any form of ischemic heart disease, significantly increased concentrations of serum immunoglobulin E were found, as compared to the control group of healthy individuals. Changes of IgE serum concentration on the 1(st) day, 7(th) day, 14(th) day and 40(th) day after AMI did not reveal any significant differences. Males with AMI turned out to have significantly higher immunoglobulin concentrations than females. The observed higher serum IgE concentration in patients with IHD may serve as evidence contribution to atherogenesis and myocardial ischemia.